Revance Therapeutics (NASDAQ:RVNC) Price Target Raised to $33.00

Revance Therapeutics (NASDAQ:RVNC) had its price objective upped by HC Wainwright from $27.00 to $33.00 in a research report sent to investors on Thursday, The Fly reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other analysts have also issued reports on the stock. BidaskClub lowered shares of Revance Therapeutics from a hold rating to a sell rating in a research report on Thursday, October 1st. Zacks Investment Research lowered shares of Revance Therapeutics from a buy rating to a hold rating in a research report on Wednesday, August 12th. Barclays upped their price target on shares of Revance Therapeutics from $32.00 to $35.00 and gave the company an overweight rating in a research report on Monday, September 28th. Finally, Mizuho initiated coverage on shares of Revance Therapeutics in a research report on Tuesday, August 11th. They set a buy rating and a $32.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. Revance Therapeutics presently has a consensus rating of Buy and a consensus price target of $30.44.

RVNC opened at $25.62 on Thursday. The stock has a market cap of $1.69 billion, a PE ratio of -6.07 and a beta of 1.73. The company has a quick ratio of 10.46, a current ratio of 10.48 and a debt-to-equity ratio of 0.68. Revance Therapeutics has a 52 week low of $11.78 and a 52 week high of $34.62. The business’s fifty day simple moving average is $27.77 and its 200 day simple moving average is $23.09.

Revance Therapeutics (NASDAQ:RVNC) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.96) by ($0.16). The firm had revenue of $0.30 million during the quarter, compared to the consensus estimate of $1.05 million. Revance Therapeutics had a negative net margin of 42,532.11% and a negative return on equity of 88.96%. As a group, equities analysts anticipate that Revance Therapeutics will post -4.18 earnings per share for the current year.

In other news, insider Aubrey Rankin sold 33,119 shares of the stock in a transaction dated Monday, September 28th. The shares were sold at an average price of $26.18, for a total transaction of $867,055.42. Following the completion of the sale, the insider now directly owns 67,871 shares in the company, valued at $1,776,862.78. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 4.80% of the company’s stock.

Several institutional investors have recently bought and sold shares of RVNC. First Trust Advisors LP purchased a new stake in shares of Revance Therapeutics during the first quarter worth about $290,000. BNP Paribas Arbitrage SA lifted its holdings in Revance Therapeutics by 198.3% in the first quarter. BNP Paribas Arbitrage SA now owns 15,695 shares of the biopharmaceutical company’s stock worth $232,000 after buying an additional 10,434 shares during the period. Nuveen Asset Management LLC lifted its holdings in Revance Therapeutics by 7.5% in the first quarter. Nuveen Asset Management LLC now owns 351,250 shares of the biopharmaceutical company’s stock worth $5,199,000 after buying an additional 24,534 shares during the period. Deutsche Bank AG lifted its holdings in Revance Therapeutics by 12.9% in the first quarter. Deutsche Bank AG now owns 175,862 shares of the biopharmaceutical company’s stock worth $2,602,000 after buying an additional 20,150 shares during the period. Finally, Legal & General Group Plc lifted its holdings in Revance Therapeutics by 4.0% in the first quarter. Legal & General Group Plc now owns 19,064 shares of the biopharmaceutical company’s stock worth $283,000 after buying an additional 738 shares during the period. Institutional investors own 76.75% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.

See Also: How to Use a Moving Average for TradingĀ 

The Fly

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.